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Objectives: Diabetic retinopathy/ DME are substantial complications leading to 
blindness. Ranibizumab (RBZ) 0.5mg and aflibercept (ABC) (anti-VEGF) change the 
DME-treatment paradigm. We estimated the cost-effectiveness of RBZ vs. ABC and 
laser from the Czech health care system perspective. MethOds: A Markov cohort 
model with 8 health states (based on visual acuity) + dead in life-time horizon (3% 
discount rate) was used. Base-line patient characteristics came from the RESTORE 
study; 60% of patients were treated for their worse seeing-eye. Patients who were 
treated in both eyes were not included in the analysis. Transition probabilities (effi-
cacy) for the first 3 years of treatment for RBZ 0.5mg and laser were derived from 
RESTORE, for ABC from a published network meta-analysis (gain at least 10 letters: 
RBZ vs. ABC: OR = 1.59; 95%CrI 0.61 – 5.37). Natural progression of disease came 
from Wisconsin Epidemiologic Study. Utility for better and worse seeing-eye were 
derived from literature. RBZ and ABC dosing came from RESTORE (pro re nata, PRN) 
and from VIVID-DME, VISTA-DME study (bi-monthly after 5 initial monthly doses), 
respectively. Cost parity per dose of anti-VEGF (€ 855) was assumed. Results: Using 
a life-time horizon, total (discounted) costs and QALYs for RBZ, ABC, laser were 
:€ 7,110; € 9,562; € 1.490 and 7.589; 7.502; 7.022 QALYs, respectively. The incremental 
costs and QALYs for RBZ vs. laser were € 5.620 and 0.567 QALYs, with base-case ICER 
of 9.918 € /QALY. RBZ vs. ABC brought 0.087 QALY gain with € 2.452 savings, reflecting 
dominance of RBZ over ABC. According to probabilistic sensitivity analysis, there 
is 64%/ 90% probability that RBZ’s ICER is below 1GDP/ 3GDP per capita (€ 13,800/ 
€ 40,000) compared to laser. There is 62% probability that RBZ compared to ABC 
brings more QALY with lower costs. cOnclusiOns: RBZ is dominant, cost-effective 
compared to ABC, laser approach, respectively in DME patients from the Czech 
health care system perspective.
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Objectives: To evaluate the cost-effectiveness of intravitreal aflibercept (IVT-AFL) 
compared with ranibizumab in the management of patients with macular oedema 
secondary to branch retinal vein occlusion (BRVO). MethOds: A 25-health-state 
Markov model considering ranges of visual acuity in both eyes was developed. 
Patients had a confirmed diagnosis of macular oedema secondary to BRVO and 
had best corrected visual acuity (BCVA) at baseline between 25 and 73 letters. The 
evaluation compared IVT-AFL 2mg with ranibizumab 0.5mg: the frequency of injec-
tions and monitoring were identical for both treatments, taken from randomised 
trials and a physician survey. A systematic review and indirect comparison were 
conducted to determine the probabilities of gaining at least 15 BCVA letters from 
baseline to 6 months; BCVA was then extrapolated over time to determine costs 
and outcomes. Utilities were taken from published literature and costs were esti-
mated from a UK payer perspective. Published drug prices were discounted to reflect 
patient access schemes. Costs and benefits were discounted at 3.5%. Results: The 
indirect comparison found that IVT-AFL was associated with a small numerical 
advantage in the likelihood of gaining 15 BCVA letters, compared with ranibizumab 
(median odds ratio = 1.08 95% Crl: 0.43-2.56). IVT-AFL was associated with a higher 
number of QALYs (0.045) per patient than ranibizumab. Both treatments are avail-
able to the National Health Service under confidential patient access schemes. Cost-
effectiveness was estimated for a range of possible discounts for each treatment. 
At price parity, IVT-AFL reduces cost by £4 per patient and was a dominant therapy. 
Resultswere sensitive to the unit cost of the drugs used, to comparative efficacy 
and number of injections for both treatments. cOnclusiOns: IVT-AFL 2mg was 
found to offer greater QALYs and to be a cost-effective option when compared with 
ranibizumab 0.5mg in the management of macular oedema secondary to BRVO.
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Objectives: This analysis assessed the value of apremilast in adult patients with 
moderate to severe chronic plaque psoriasis who have failed to respond to, have 
a contraindication to, or are intolerant to other systemic therapy in the Italian 
setting. MethOds: A Markov state-transition cohort model was adapted to the 
Italian setting to compare costs and quality-adjusted life years (QALYs) from 2 
treatment sequences: apremilast, etanercept, adalimumab, ustekinumab, best sup-
portive care (BSC) vs. etanercept, adalimumab, ustekinumab, BSC. The time hori-
zon was 5 years, and a 28-day cycle was used. The National Health Service (NHS) 
perspective was chosen. Data on treatment efficacy (based on ≥ 75% improvement 
in Psoriasis Area and Severity Index [PASI-75] response rate) were taken from a 
network meta-analysis that included 22 clinical trials (2001-2013). Resource use 
and unit costs were taken from Italian standard sources. Frequency of screening 
and monitoring tests was obtained from real-world data (database analysis). Utility 
weights associated with PASI states were taken from a UK NHS health technology 
assessment appraisal. A 3% discount rate was applied to costs and benefits. Both 
deterministic and probabilistic sensitivity analyses were performed. Results: 
In the base case, the sequence including apremilast was dominant, with cost 
savings of € 1,169 (€ 57,965 vs. € 59,134) and 0.01 QALYs gained (3.96 vs. 3.95) over 5 
Objectives: The objective was to estimate the CoD in wAMD, in Turkish set-
ting. MethOds: An expert panel was held by participation of five ophthalmologists 
to discuss the disease management in wAMD. Physicians reviewed the literature, 
discussed the local clinical practices and all cost components; pharmaceuticals, 
treatment administration, monitoring, adverse events and blindness. The clinical/
economic parameters were entered as inputs of a Markov model mimicking the 
follow-up of patients up to 20 years. Cost of ranibizumab treatment was studied. 
September-2014 local prices for medications and procedures were used as sources. 
September-2014 EUR currency rate (2.8671TL/EUR) was used. Results: The fre-
quency of treatments and outpatient visits in a year were assumed as 12 for the 
first year and 6 for the second year. Fluorescein angiography was assumed to be 
performed every six months. Total cost of blindness was estimated as 2,964EUR/
year. The components of overall blindness cost include impairment salary in all 
(1,777EUR), home care services in 30% (990EUR), telescopic vision aid in one-thirds 
(96EUR), hip prosthesis operation, including prosthesis in 5% (64EUR), psychiatric 
management in 30% (32EUR) and visually impaired rehabilitation in 11% (6EUR). CoD 
calculation was started with the first implementation of treatment. The total cost 
for first year was 5,269EUR. The cost components included pharmaceutical costs 
(ranibizumab 4,915EUR), treatment administration (71-121EUR), monitoring (138-
208EUR), adverse events (0-2EUR) and blindness (23EUR). The average yearly costs 
(calculated according to the cumulative five and twenty-year costs) were 1,864EUR 
and 1,110EUR in patients treated with ranibizumab. cOnclusiOns: The treatment 
cost formed the major part of the total CoD in the first year of treatment. With the 
increasing number of patients getting blind throughout the years, the cost of blind-
ness advanced to the first place.
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Objectives: Published data regarding indirect (or work-related productivity) 
costs in psoriasis are limited. We sought to estimate indirect costs of moder-
ate-to-severe plaque psoriasis dependent on the level of psoriasis improvement 
(Psoriasis Activity Severity Index [PASI] change) due to treatment. MethOds: 
Work Productivity and Activity Impairment Questionnaire Psoriasis (WPAI-PSO) 
data from a recent clinical trial (CLEAR) were analyzed by PASI change at 16 weeks. 
Using reported data for work impairment due to psoriasis for trial subjects who 
were employed at baseline and data from national employment averages (full- vs. 
part-time employment, work hours/week, hourly wages), we estimated weekly 
and annual indirect costs by PASI change for moderate-to-severe plaque pso-
riasis patients in Germany. Results: Overall work impairment due to psoriasis 
decreased with greater skin clearance (PASI change < 50= 23.8%, 50-74= 13.3%, 
75-89= 6.4%, ≥ 90= 4.9%), with the majority of impairment being related to produc-
tivity loss at work (presenteeism) rather than absenteeism. On average, patients 
working with poorly controlled (PASI change < 50) moderate-to-severe psoriasis 
lost > 8 hours a week of productive work time due to psoriasis symptoms; while 
productivity loss for patients with high clearance (PASI change ≥ 90) was small (< 2 
hours/week). From a societal perspective (includes patients not working), indirect 
costs per patient per week were estimated to be € 117 for PASI change < 50, € 68 for 
50-74, € 33 for 75-89, and € 25 for ≥ 90. Restricting the population to those employed 
at baseline (employer’s perspective), indirect costs per employed patient per week 
decreased from € 174 (PASI change < 50) to € 38 (PASI change ≥ 90). Annual indirect 
costs from the societal perspective decreased from € 6,080 (PASI change < 50) to 
€ 1,316 (PASI change ≥ 90) per patient. cOnclusiOns: Based on our estimates, PASI 
improvement of ≥ 90 is linked to a prominent increase in workplace productivity 
and reduction in indirect costs in moderate-to-severe psoriasis patients from both 
the societal and employer perspectives.
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Objectives: To determine the direct costs associated with high myopia (HM) 
patients with and without choroidal neovascularisation (mCNV). MethOds: 
Observational, retrospective, multicentre study in adult patients selected consecu-
tively with HM with/without mCNV. The patient characteristics, clinical course and 
use of health resources were recorded. Patients reported the use of assistive devices 
and employment status from diagnosis. Annual direct medical costs (AMC, from 
the perspective of the National Health System) and direct non-medical costs were 
estimated (AnMC) [€ , January 2014]. Differences were assessed using Chi-square 
(or Fisher exact), Mann-Whitney or Kruskal-Wallis (Bonferroni contrast) tests. A 
multivariate regression analysis was done (General Linear Model, GLM). Results: A 
total of 137 mCNV and 48 HM patients were included (mean of age±SD: 55.1±12.8 vs. 
54.7±13.8 years, respectively; p= 0.2). 80% were women in both groups. The observa-
tion time ranged from 17.9±9.6 to 20.0±9.7 months in mCNV and from 47.1±21.5 to 
45.5±20.7 months in HM. In mCNV patients, a greater need for visits to the emer-
gency room (41.7% vs. 25%; p= 0.06) and retinal specialists (91.2% vs. 77.1%; p= 0.01) 
was found. The AMC was higher in mCNV patients 1,985 € (95% CI 1,772-2,198) vs. 356 
€ (251-480), p< 0.001. The AnMC was also higher in mCNV patients 256 € (11-524) vs. 
19 € (11-26); p> 0.4. Healthcare costs were not homogeneous in all geographic areas 
(p= 0.002). The number of affected eyes, the follow-up time and mCNV were factors 
associated to the direct cost (according to the GLM). The impact on job performance 
was higher in mCNV vs. HM (fairly or very affected) 27.7% vs. 10.4%. cOnclusiOns: 
The mCNV implies higher health costs than HM. Moreover, mCNV patients have a 
greater need of care and assistive devices, and a greater impact on their working life.
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IVT-AFL 2q8 versus ranibizumab 0.5q4, and an indirect comparison of IVT-AFL 
2q8 with ranibizumab 0.5PRN data. A de novo health economic model combined 
these clinical inputs with Dutch-specific costs associated with treatment, moni-
toring, and indirect caregiving, and utility inputs relevant to a Dutch popula-
tion. Total quality-adjusted life-years (QALYs) and costs were calculated over a 
15-year horizon. Uncertainty around the outcomes was tested through sensitivity 
analyses. Results: Compared with ranibizumab 0.5q4, a 2-year treatment IVT-
AFL is associated with a significantly lower cost of € 7337 (95% CI: € 7248–€ 7435) 
over a 15-year horizon. There is no significant difference in QALYs (–0.0027 [95% 
CI: –0.0057 to 0.0001]). IVT-AFL 2q8 also has significantly lower total costs than 
ranibizumab 0.5PRN (€ 2450 [95% CI: € 2349–€ 2549]), with a nonsignificant gain of 
0.0007 QALYS (95% CI: –0.0023 to 0.0036). Probabilistic analyses show that, due to 
its lower costs, IVT-AFL 2q8 treatment had an estimated > 99% probability of being 
cost-effective compared with both of the ranibizumab treatment strategies at a 
willingness-to-pay threshold of € 20,000 per QALY, the proposed informal Dutch 
threshold. The univariate analyses did not alter the conclusions. cOnclusiOns: 
The analysis showed that IVT-AFL 2q8 treatment is associated with cost savings 
versus ranibizumab 0.5q4 or 0.5PRN. There is no significant difference in total 
QALYs between the treatments. Due to lower overall costs, IVT-AFL is a cost-
effective treatment option for wAMD patients in the Netherlands.
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Objectives: A cost-utility model was developed to assess the impact of plac-
ing apremilast, a new oral treatment, before biologics in patients with moderate 
to severe plaque psoriasis who have failed to respond to, have a contraindica-
tion to, or are intolerant to other systemic treatments from a Spain payer per-
spective. MethOds: A 20-year Markov model with monthly cycle duration was 
developed. Treatment strategies consisted of apremilast prior to a biologic drug 
sequence compared with a biologic-only sequence. Sequential biologics, based 
on Spanish clinical practice, were adalimumab, ustekinumab, etanercept, and 
infliximab for both strategies. Patients who failed infliximab were assumed to 
receive best supportive care. A ≥ 75% reduction in Psoriasis Area and Severity 
Index was used as the efficacy measure. Drug response rates were derived from 
a meta-analysis. All-cause overall mortality was considered. Resource consump-
tion was estimated by an expert panel; biologic doses were taken from sum-
maries of the product characteristics. According to the NHS perspective, total 
costs included drug acquisition (ex-factory price with mandatory deduction), 
administration (parenteral drugs), and monitoring costs. Unit costs (€ , 2014) were 
obtained from national databases. An annual discount rate of 3% was applied for 
costs and health benefits. Utilities were estimated from PASI response using a 
published regression equation. Sensitivity analyses were performed to test model 
robustness. Results: The administration of apremilast before a sequence of bio-
logic drugs was estimated to provide an additional 0.12 quality-adjusted life-years 
(QALYs): 12.37 QALYs vs. 12.25 QALYs with the biologic-only sequence. In the 
base-case assumptions, the apremilast sequence yielded lower total costs vs. the 
biologic-only sequence (€ 216,490 vs. € 224,359). cOnclusiOns: The administration 
of apremilast before biologic drugs is a cost-saving strategy for the NHS in the 
treatment of patients with moderate to severe plaque psoriasis. This analysis was 
limited in that the model did not consider cost-effectiveness issues.
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Objectives: To estimate the incremental cost-effectiveness ratio (ICER) of intra-
vitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic 
macular oedema (DMO) in Sweden. MethOds: A Markov model was developed 
targeting patients with visual impairment due to DMO in Sweden, based on data 
from the VIVID/VISTA and RESTORE clinical trials. A one-eye model was used in 
base case and patients were followed according to visual acuity in their study eye 
with a time horizon of 15 years. Eight mutually exclusive, exhaustive health states 
were specified and defined in terms of ETDRS letters read. Benefits were measured 
with utility specified as a function of the visual acuity of both eyes in combination. 
The main outcome was incremental cost per additional quality-adjusted life-years 
(QALYs) evaluated from a societal perspective. Univariate and probabilistic sensitiv-
ity analyses (PSA), and scenario analyses were conducted. Results: Intravitreal 
aflibercept was shown to be cost-effective versus intravitreal ranibizumab with 
an ICER of 128,323 (€ 13,821) SEK/QALY gained. The higher total cost for intravitreal 
aflibercept compared to intravitreal ranibizumab predominantly reflected the drug 
and administration costs while intravitreal ranibizumab showed a higher cost for 
monitoring. The incremental cost and QALYs were estimated to 5,227 SEK (€ 563) 
and 0.041, respectively. Univariate sensitivity analyses showed that the ICER was 
sensitive to the number of treatments and the administration costs. PSA showed 
that with a willingness-to-pay threshold of 500,000 SEK/QALY intravitreal aflibercept 
was estimated to have 68% chance of being cost-effective compared with intravitreal 
ranibizumab. In a number of scenarios, intravitreal aflibercept was estimated to 
be cost-effective against intravitreal ranibizumab including: four different sets of 
utilities; adjustment of treatment duration and discount rates; different time hori-
zons and with and without indirect costs. cOnclusiOns: In Sweden, intravitreal 
aflibercept may be a cost-effective option versus intravitreal ranibizumab for the 
treatment of DMO using 500 TSEK as threshold.
years. This sequence remained dominant or cost saving in all the deterministic 
sensitivity analyses, changing efficacy data, utility weights, or discount rates. 
Resultswere more sensitive to changes in the time horizon of the analysis. The 
probabilistic sensitivity analysis confirmed that the apremilast sequence was 
dominant or cost saving in a large majority of the simulations. cOnclusiOns: 
This analysis suggests that the use of apremilast for treatment of moderate to 
severe psoriasis may represent a cost-saving option for the Italian NHS without 
any loss in patients’ quality of life.
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Objectives: Choroidal neovascularization (CNV) is the most common vision-
threatening complication associated with pathologic myopia (PM), a progressive 
condition characterized by axial elongation and degenerative changes in the 
posterior segment of the eye. This study aimed to evaluate the cost effective-
ness of ranibizumab compared with verteporfin photodynamic therapy (vPDT) 
in patients with visual impairment due to myopic CNV in the Portuguese set-
ting. MethOds: A Markov model was developed with health states defined by 
best-corrected visual acuity and a 3-month cycle length. The study has taken 
under National Health Service perspective and included societal perspective in 
an alternative scenario, considering a lifetime time horizon. The study was based 
on 2013 prices considering future costs and health outcomes to be discounted at 
5.0% per annum. The baseline characteristics considered were retrieved from the 
phase III RADIANCE study (Ranibizumab and vPDT Evaluation in Myopic CNV), and 
VIP study (Verteporfin in Photodynamic Therapy). Extensive sensitivity analyses 
tested the robustness of the model. Results: From NHS perspective, the lifetime 
cost of treating myopic CNV with ranibizumab was € 8,241.73 whereas vPDT was 
associated with a total cost of € 10,732.81. In the alternative scenario, from societal 
perspective those costs amount to € 8,815.22 and € 11.333,83, for ranibizumab and 
vPDT, respectively. Ranibizumab treatment produced higher cumulative quality-
adjusted life-years (QALYs; 8.95) than vPDT (8.70). Ranibizumab treatment was 
therefore dominant in both scenarios, with greater health gains and lower overall 
costs than vPDT. In the probabilistic sensitivity analysis, ranibizumab had a 100% 
probability of being cost effective compared with vPDT, at an informal willingness-
to-pay threshold of € 30.000/QALY. cOnclusiOns: This cost effectiveness study 
indicates that the therapy with ranibizumab is dominant over vPDT for the treat-
ment of visual impairment due to CNV secondary to pathologic myopia from both 
NHS and society perspectives.
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Objectives: The optimal treatment strategy for moderate to severe plaque 
psoriasis remains to be determined. In its absence, switching between various 
treatment options, especially biologics, is a common practice among prescribers. 
We assessed the cost-effectiveness of placing a new oral treatment, apremilast, 
before biologics for moderate to severe plaque psoriasis from a Scottish payer 
perspective. MethOds: A 10-year Markov transition cohort model was developed 
comparing alternative treatment sequences: (1) apremilast followed by etanercept 
followed by adalimumab and (2) adalimumab followed by etanercept. Patients 
failing etanercept received best supportive care (BSC) as last line of treatment 
in both sequences. Response was defined as a 75% reduction in Psoriasis Area 
and Severity Index (PASI) score at the end of the trial periods (12-16 weeks). Non-
responders moved to the next treatment line. A 20% all-cause annual dropout 
rate was assumed for each treatment. Efficacy inputs were obtained from a net-
work meta-analysis. Unit costs were sourced from the British National Formulary, 
NHS reference costs, and other published sources. A 3.5% annual discount rate 
was applied to costs and quality-adjusted life-years (QALYs). Utility gains by PASI 
response were obtained from a published regression equation. Results: Placing 
apremilast before biologics was a dominant strategy. The apremilast arm pro-
vided an additional 0.74 years in which patients achieved a 75% reduction from 
baseline PASI score and an additional 0.09 QALYs (7.00 vs. 6.91 QALYs). Total time 
spent on biologics and in BSC was reduced by 0.47 and 1.01 years, respectively. 
Total costs were reduced by £3,206. Sensitivity analyses showed robust results. 
Similar Resultswere obtained when combinations of other biologics, including 
ustekinumab, were used in a 2- or 3-drug sequence. cOnclusiOns: Placing 
apremilast before biologics is a dominant strategy in moderate to severe plaque 
psoriasis treatment.
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Objectives: This study investigates the cost-effectiveness of 2 mg IVT-AFL every 
8 weeks (2q8), after 3 monthly starting doses, compared with 0.5 mg ranibizumab 
every 4 weeks (0.5q4) and a strategy of a 3-month 0.5q4 starting dose ranibizumab 
followed by 0.5 mg every 4–12 weeks as needed (0.5PRN) with 2-year treatment 
durations in Dutch wAMD patients. MethOds: A cost-effectiveness analysis was 
conducted, utilising clinical data from head-to-head randomised clinical trials of 
